Overview

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Status:
Completed
Trial end date:
2017-04-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences